123 related articles for article (PubMed ID: 16697762)
1. Adalimumab induction for Crohn's disease.
Cottone M; Mocciaro F; Scimeca D
Gastroenterology; 2006 May; 130(6):1929. PubMed ID: 16697762
[No Abstract] [Full Text] [Related]
2. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.
Colombel JF; Sandborn WJ; Rutgeerts P; Kamm MA; Yu AP; Wu EQ; Pollack PF; Lomax KG; Chao J; Mulani PM
Am J Gastroenterol; 2009 May; 104(5):1170-9. PubMed ID: 19352339
[TBL] [Abstract][Full Text] [Related]
3. CLASSIC-I study the efficacy of adalimumab.
Schreiber S; Sandborn WJ
Gastroenterology; 2006 May; 130(6):1929-30. PubMed ID: 16697761
[No Abstract] [Full Text] [Related]
4. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.
Colombel JF; Sandborn WJ; Rutgeerts P; Enns R; Hanauer SB; Panaccione R; Schreiber S; Byczkowski D; Li J; Kent JD; Pollack PF
Gastroenterology; 2007 Jan; 132(1):52-65. PubMed ID: 17241859
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.
Trinder MW; Lawrance IC
J Gastroenterol Hepatol; 2009 Jul; 24(7):1252-7. PubMed ID: 19220669
[TBL] [Abstract][Full Text] [Related]
6. CDP870 in Crohn's disease: reconsidering endpoints.
Winter TA; de Villiers WJ; Mardini HE
Inflamm Bowel Dis; 2006 Mar; 12(3):249. PubMed ID: 16534429
[No Abstract] [Full Text] [Related]
7. Adalimumab in patients with Crohn's disease--safety and efficacy in an open-label single centre study.
Seiderer J; Brand S; Dambacher J; Pfennig S; Jürgens M; Göke B; Ochsenkühn T
Aliment Pharmacol Ther; 2007 Apr; 25(7):787-96. PubMed ID: 17373917
[TBL] [Abstract][Full Text] [Related]
8. Adalimumab for Crohn's disease with intolerance or lost response to infliximab: a 3-year single-centre experience.
Oussalah A; Babouri A; Chevaux JB; Stancu L; Trouilloud I; Bensenane M; Boucekkine T; Bigard MA; Peyrin-Biroulet L
Aliment Pharmacol Ther; 2009 Feb; 29(4):416-23. PubMed ID: 19035976
[TBL] [Abstract][Full Text] [Related]
9. Frequency and predictors of loss of response to infliximab or adalimumab in Crohn's disease after one-year treatment period - a single center experience.
Molnár T; Farkas K; Nyári T; Szepes Z; Nagy F; Wittmann T
J Gastrointestin Liver Dis; 2012 Sep; 21(3):265-9. PubMed ID: 23012667
[TBL] [Abstract][Full Text] [Related]
10. Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study.
Peyrin-Biroulet L; Laclotte C; Bigard MA
Aliment Pharmacol Ther; 2007 Mar; 25(6):675-80. PubMed ID: 17311600
[TBL] [Abstract][Full Text] [Related]
11. Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease.
Panaccione R; Colombel JF; Sandborn WJ; Rutgeerts P; D'Haens GR; Robinson AM; Chao J; Mulani PM; Pollack PF
Aliment Pharmacol Ther; 2010 Jun; 31(12):1296-309. PubMed ID: 20298496
[TBL] [Abstract][Full Text] [Related]
12. Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and naïve patients.
Swaminath A; Ullman T; Rosen M; Mayer L; Lichtiger S; Abreu MT
Aliment Pharmacol Ther; 2009 Feb; 29(3):273-8. PubMed ID: 19006540
[TBL] [Abstract][Full Text] [Related]
13. Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy.
Oussalah A; Chevaux JB; Fay R; Sandborn WJ; Bigard MA; Peyrin-Biroulet L
Am J Gastroenterol; 2010 May; 105(5):1142-9. PubMed ID: 20389296
[TBL] [Abstract][Full Text] [Related]
14. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study.
Feagan BG; Panaccione R; Sandborn WJ; D'Haens GR; Schreiber S; Rutgeerts PJ; Loftus EV; Lomax KG; Yu AP; Wu EQ; Chao J; Mulani P
Gastroenterology; 2008 Nov; 135(5):1493-9. PubMed ID: 18848553
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease.
West RL; Zelinkova Z; Wolbink GJ; Kuipers EJ; Stokkers PC; van der Woude CJ
Aliment Pharmacol Ther; 2008 Nov; 28(9):1122-6. PubMed ID: 18691349
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of adalimumab in moderate-to-severe pediatric Crohn's disease.
Viola F; Civitelli F; Di Nardo G; Barbato MB; Borrelli O; Oliva S; Conte F; Cucchiara S
Am J Gastroenterol; 2009 Oct; 104(10):2566-71. PubMed ID: 19550415
[TBL] [Abstract][Full Text] [Related]
17. Biologics for inflammatory bowel diseases in the Asia-Pacific: can we afford to use them, can we afford not to?
Gearry RB; Irving PM
J Gastroenterol Hepatol; 2009 Jul; 24(7):1160-2. PubMed ID: 19682189
[No Abstract] [Full Text] [Related]
18. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.
Hyams J; Crandall W; Kugathasan S; Griffiths A; Olson A; Johanns J; Liu G; Travers S; Heuschkel R; Markowitz J; Cohen S; Winter H; Veereman-Wauters G; Ferry G; Baldassano R;
Gastroenterology; 2007 Mar; 132(3):863-73; quiz 1165-6. PubMed ID: 17324398
[TBL] [Abstract][Full Text] [Related]
19. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial.
Loftus EV; Feagan BG; Colombel JF; Rubin DT; Wu EQ; Yu AP; Pollack PF; Chao J; Mulani P
Am J Gastroenterol; 2008 Dec; 103(12):3132-41. PubMed ID: 18853973
[TBL] [Abstract][Full Text] [Related]
20. Survey on the use of adalimumab as maintenance therapy in Crohn's disease in England and Ireland.
Russo EA; Iacucci M; Lindsay JO; Campbell S; Hart A; Hamlin J; Orchard T; Arebi N; Nightingale J; Jacyna MR; Gabe SM; O'Connor M; Harris AW; O'Morain C; Ghosh S
Eur J Gastroenterol Hepatol; 2010 Mar; 22(3):334-9. PubMed ID: 19528808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
